Cargando…

Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015

BACKGROUND: Temporal trends in clinical composition and outcome in dilated cardiomyopathy (DCM) are largely unknown, despite considerable advances in heart failure management. We set out to study clinical characteristics and prognosis over time in DCM in Sweden during 2003–2015. METHODS: DCM patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjöland, Helen, Silverdal, Jonas, Bollano, Entela, Pivodic, Aldina, Dahlström, Ulf, Fu, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212489/
https://www.ncbi.nlm.nih.gov/pubmed/34144681
http://dx.doi.org/10.1186/s12872-021-02124-0
_version_ 1783709649119215616
author Sjöland, Helen
Silverdal, Jonas
Bollano, Entela
Pivodic, Aldina
Dahlström, Ulf
Fu, Michael
author_facet Sjöland, Helen
Silverdal, Jonas
Bollano, Entela
Pivodic, Aldina
Dahlström, Ulf
Fu, Michael
author_sort Sjöland, Helen
collection PubMed
description BACKGROUND: Temporal trends in clinical composition and outcome in dilated cardiomyopathy (DCM) are largely unknown, despite considerable advances in heart failure management. We set out to study clinical characteristics and prognosis over time in DCM in Sweden during 2003–2015. METHODS: DCM patients (n = 7873) from the Swedish Heart Failure Registry were divided into three calendar periods of inclusion, 2003–2007 (Period 1, n = 2029), 2008–2011 (Period 2, n = 3363), 2012–2015 (Period 3, n = 2481). The primary outcome was the composite of all-cause death, transplantation and hospitalization during 1 year after inclusion into the registry. RESULTS: Over the three calendar periods patients were older (p = 0.022), the proportion of females increased (mean 22.5%, 26.4%, 27.6%, p = 0.0001), left ventricular ejection fraction was higher (p = 0.0014), and symptoms by New York Heart Association less severe (p < 0.0001). Device (implantable cardioverter defibrillator and/or cardiac resynchronization) therapy increased by 30% over time (mean 11.6%, 12.3%, 15.1%, p < 0.0001). The event rates for mortality, and hospitalization were consistently decreasing over calendar periods (p < 0.0001 for all), whereas transplantation rate was stable. More advanced physical symptoms correlated with an increased risk of a composite outcome over time (p = 0.0043). CONCLUSIONS: From 2003 until 2015, we observed declining mortality and hospitalizations in DCM, paralleled by a continuous change in both demographic profile and therapy in the DCM population in Sweden, towards a less affected phenotype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02124-0.
format Online
Article
Text
id pubmed-8212489
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82124892021-06-22 Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015 Sjöland, Helen Silverdal, Jonas Bollano, Entela Pivodic, Aldina Dahlström, Ulf Fu, Michael BMC Cardiovasc Disord Research BACKGROUND: Temporal trends in clinical composition and outcome in dilated cardiomyopathy (DCM) are largely unknown, despite considerable advances in heart failure management. We set out to study clinical characteristics and prognosis over time in DCM in Sweden during 2003–2015. METHODS: DCM patients (n = 7873) from the Swedish Heart Failure Registry were divided into three calendar periods of inclusion, 2003–2007 (Period 1, n = 2029), 2008–2011 (Period 2, n = 3363), 2012–2015 (Period 3, n = 2481). The primary outcome was the composite of all-cause death, transplantation and hospitalization during 1 year after inclusion into the registry. RESULTS: Over the three calendar periods patients were older (p = 0.022), the proportion of females increased (mean 22.5%, 26.4%, 27.6%, p = 0.0001), left ventricular ejection fraction was higher (p = 0.0014), and symptoms by New York Heart Association less severe (p < 0.0001). Device (implantable cardioverter defibrillator and/or cardiac resynchronization) therapy increased by 30% over time (mean 11.6%, 12.3%, 15.1%, p < 0.0001). The event rates for mortality, and hospitalization were consistently decreasing over calendar periods (p < 0.0001 for all), whereas transplantation rate was stable. More advanced physical symptoms correlated with an increased risk of a composite outcome over time (p = 0.0043). CONCLUSIONS: From 2003 until 2015, we observed declining mortality and hospitalizations in DCM, paralleled by a continuous change in both demographic profile and therapy in the DCM population in Sweden, towards a less affected phenotype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02124-0. BioMed Central 2021-06-18 /pmc/articles/PMC8212489/ /pubmed/34144681 http://dx.doi.org/10.1186/s12872-021-02124-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sjöland, Helen
Silverdal, Jonas
Bollano, Entela
Pivodic, Aldina
Dahlström, Ulf
Fu, Michael
Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title_full Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title_fullStr Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title_full_unstemmed Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title_short Temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the Swedish Heart Failure Registry 2003–2015
title_sort temporal trends in outcome and patient characteristics in dilated cardiomyopathy, data from the swedish heart failure registry 2003–2015
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212489/
https://www.ncbi.nlm.nih.gov/pubmed/34144681
http://dx.doi.org/10.1186/s12872-021-02124-0
work_keys_str_mv AT sjolandhelen temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015
AT silverdaljonas temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015
AT bollanoentela temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015
AT pivodicaldina temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015
AT dahlstromulf temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015
AT fumichael temporaltrendsinoutcomeandpatientcharacteristicsindilatedcardiomyopathydatafromtheswedishheartfailureregistry20032015